Investor Dashboard

Company Tear Sheet

Corporate profile

We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our phosphoramidate chemistry technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid tumours, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilising our proprietary ProTide technology, we are developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

SEC Filings

Filing date Description

An amendment to the SC 13G filing

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Registration of securities of foreign private issuers pursuant to section 12(b) or (g)

An amendment to the SC 13G filing

A statement of beneficial ownership of common stock by certain persons